Moderna posts surprise profit as COVID vaccine sales exceed expectations

November 07, 2024 06:46 AM PST | By Invezz
 Moderna posts surprise profit as COVID vaccine sales exceed expectations
Image source: Invezz

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of its COVID-19 vaccine, despite lower-than-anticipated revenue from its new respiratory syncytial virus (RSV) vaccine.

Shares of the Cambridge, Massachusetts-based company jumped 11% in premarket trading.

For the quarter, Moderna posted a profit of $13 million, or 3 cents per share, compared to a loss of $3.6 billion in the same period last year.

Analysts had expected a loss of $753 million, or $1.90 per share, according to LSEG data, Reuters reported.

Sales of its Spikevax COVID vaccine reached $1.8 billion, up 3.5% year-over-year, surpassing analysts’ expectations of $1.38 billion.

The company attributed this strong performance to increased sales in the US following an early launch of the vaccine this year.

The US Food and Drug Administration approved updated versions of Spikevax and Pfizer’s Comirnaty nearly three weeks earlier than in 2023.

Moderna noted that international sales of Spikevax were lower compared to the same period in 2023 when sales were boosted by deferred orders from 2022.

Operating expenses for the quarter totaled $1.93 billion, nearly 50% lower than the previous year, largely due to reduced unused manufacturing capacity and fewer inventory write-downs.

RSV vaccine, mRESVIA, generate $10 million in sales

The company’s new RSV vaccine, mRESVIA, generated $10 million in sales, falling significantly short of the $135 million analysts had expected. Despite this, Moderna reaffirmed its annual sales forecast of $3 billion to $3.5 billion.

“This guidance looks well within reach, especially with strong expected sales in Q4 from the COVID vaccine,” said TD Cowen analyst Tyler Van Buren.

Moderna is increasingly relying on revenue from newer mRNA vaccines, such as mRESVIA and an experimental COVID-19 combination vaccine, to offset declining demand for COVID-19 products post-pandemic.

Mock explained that the company struggled to compete during the peak of the RSV contracting season because mRESVIA was approved later in the year, and many contracts and inventory had already been secured.

US market share for Spikevax fell to 40%, down from 45% in Q3 2023. Moderna reported that 7.5 million patients received Spikevax this year, compared to nearly 11 million people who received Pfizer’s COVID-19 vaccine during the same period, according to IQVIA data.

The post Moderna posts surprise profit as COVID vaccine sales exceed expectations appeared first on Invezz


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next